Compare Edison International Common Stock (EIX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edison International Common Stock vs Tango Therapeutics Inc. — how do they compare? Edison International Common Stock trades at $55.9 (market cap $21.35B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Edison International Common Stock is far larger — about 5.7× Tango Therapeutics Inc.'s market cap, and Edison International Common Stock pays a 6.33% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edison International Common Stock for 4 Days and Tango Therapeutics Inc. for 0 Days on average.
| EIX | TNGX | |
|---|---|---|
Market Cap | $21.35B | $3.74B |
Volume | 15,485,731 | 3,438,781 |
Sector | Utilities | Health |
52-Week High | $80.38 | $32.90 |
52-Week Low | $51.47 | $7.50 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $64.73B | $2.76B |
Dividend Yield | 6.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edison International (EIX) trades at $55.48, down 0.29% on the day, with a bullish technical signal despite mixed oscillators. The stock offers a high dividend yield of 6.4% and trades below the consensus price target of $59.29. Recent earnings have consistently beaten estimates, with Q3 2026 results pending. However, the stock faces headwinds from unresolved California wildfire liability risks, contributing to a 23% decline in late August 2026.
EIX presents a value opportunity with low P/E (5.73) and P/B (1.22) ratios, strong profitability (ROE 23.06%), and a stable dividend. Key risks include regulatory uncertainty around wildfire costs and a projected decline in 2026 net margin. Analyst sentiment is mixed but leans positive, with 40.5% buy ratings. The stock's upside depends on regulatory clarity and sustained earnings growth.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edison International Common Stock
Edison International is the parent company of Southern California Edison, an electric utility that supplies and delivers electricity across Southern California. It also owns Trio, an energy advisory business.
Read more on EIX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
